# NEKTAR THERAPEUTICS (NKTR) FY2026 Q2 Balance Sheet

- Company: NEKTAR THERAPEUTICS (NKTR)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-14, accession number 0001193125-26-349805
- Page: https://plicit.ai/financials/nktr/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/nktr-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,095,129,000 US dollars
- **Current assets**: 739,402,000 US dollars
- **Non-current assets**: 355,727,000 US dollars
- **Liabilities**: 192,008,000 US dollars
- **Current liabilities**: 70,985,000 US dollars
- **Non-current liabilities**: 121,023,000 US dollars
- **Equity**: 903,121,000 US dollars
- **Short-term investments**: 645,074,000 US dollars
- **Other current assets (including $0 and $429 as of June 30, 2026 and December 31, 2025, respectively, from a related party)**: 55,061,000 US dollars
- **Cash and cash equivalents**: 39,267,000 US dollars
- **Long-term investments**: 339,061,000 US dollars
- **Other assets**: 16,666,000 US dollars
- **Accounts payable (including $456 and $137 as of June 30, 2026 and December 31, 2025, respectively, to a related party)**: 24,891,000 US dollars
- **Accrued expenses (including $130 and $994 as of June 30, 2026 and December 31, 2025, respectively, to a related party)**: 23,388,000 US dollars
- **Operating lease liabilities, current portion**: 22,706,000 US dollars
- **Liabilities related to the sales of future royalties, net**: 57,378,000 US dollars
- **Operating lease liabilities, less current portion**: 55,850,000 US dollars
- **Other long-term liabilities**: 7,795,000 US dollars
- **Capital in excess of par value**: 4,750,686,000 US dollars
- **Common stock, $0.0001 par value; 390,000,000 shares authorized; 34,129,664 shares and 20,378,832 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively**: 3,000 US dollars
- **Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at June 30, 2026 or December 31, 2025, respectively**: 0 US dollars
- **Accumulated deficit**: negative 3,845,812,000 US dollars
- **Accumulated other comprehensive income (loss)**: negative 1,756,000 US dollars
- **Gross equity (calculated)**: 4,750,689,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.